SoftBank founder Masayoshi Son speaks in futuristic terms about his company, but the success of his late-stage VC fund is still unknown.Technologyread more
Trump's threat, posted on Twitter, comes amid rising international tensions in the Middle East as the U.S. has dispatched a carrier strike group and bomber task force to the...Politicsread more
Reports of Tesla vehicles spontaneously catching fire could make customers wary of EVs just as the industry ramps up production plans.Autosread more
Amazon's large and flashy investments stand out from those of its tech peers over the past year.Technologyread more
Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
Robert Smith announced that he and his family would set up a grant to pay off the nearly 400 graduating seniors' student loans. The total gift is estimated at $40 million.Educationread more
Trump's relationships with Deutsche Bank have drawn scrutiny in Congress and elsewhere. Trump sued the bank last month to prevent it from complying with Congressional...Financeread more
Consumer IPOs from Snap to Uber have been disappointing and serve as a reminder that private investors are making all the money.Technologyread more
China's currency has been an important barometer for progress in U.S.-Chinese trade talks, and right now it's signaling things aren't going well.Market Insiderread more
The outrage has even inspired a Change.org petition called "Remake Game of Thrones Season 8 with competent writers," with over half-a-million signatories and climbing.Entertainmentread more
The move comes after star runner Alysia Montaño's May 12 op-ed in the New York Times in which she detailed her experiences with Nike.Retailread more
(Adds details from press briefing)
May 8 (Reuters) - The Trump administration on Wednesday said it will require drugmakers to disclose the list price of prescription drugs in direct-to-consumer television advertisements, part of the government's efforts to lower costs for U.S. consumers.
The list price would be included if it is equal to or greater than $35 for a month's supply or the usual course of therapy. The U.S. Department of Health and Human Services (HHS) said that the 10 most commonly advertised drugs have list prices ranging from $488 to $16,938 per month or usual course of therapy.
"The vast majority of Americans struggling to afford their drugs are put in that position because they are paying based on high list prices," HHS Secretary Alex Azar said in a press briefing.
Azar said that the TV advertising requirement would work to drive down list prices alongside a recently proposed rule aimed at requiring that drug rebates, or discounts, be passed on to Medicare patients when they buy the drugs.
The advertising rule, which was finalized on Wednesday, will take effect in about 60 days. It was originally suggested as part of President Donald Trump's "blueprint" to lower U.S. drug prices last May.
Health and Human Services said that enforcement of the rule would be done by competitors, who can sue under the Lanham Act, a 1946 U.S. law that prohibits false advertising. Those suits would accuse drugmakers of false advertising if they do not include the information, because they would be implicitly suggesting that their product costs less than $35 a month.
Azar said the agency settled on the $35 a month benchmark because that is a common copayment paid by patients filling their monthly prescriptions.
Most drug companies have argued against the proposed rule, saying list prices do not reflect the final amount paid by patients as it excludes rebates and discounts drugmakers may offer.
But Johnson & Johnson has already started including the list price - as well as potential out of pocket costs - in some of its ads.
Under the new rule, the ads can include language saying that if patients have health insurance that covers drugs, their costs may be different.
The Pharmaceutical Research and Manufacturers of America (PhRMA), the industry's top U.S. lobbying group, said in October that including the list price in commercials could discourage patients from seeking needed medical care. The group did not immediately comment on the finalized rule.
(Reporting by Caroline Humer and Michael Erman in New York; Additional reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila, Andrea Ricci and Steve Orlofsky)